Full text is available at the source.
Abstract
Oral glucagon-like peptide-1 (GLP-1) receptor agonists may influence obesity management policies in the UK.
- Obesity is a significant health issue in the UK, leading to increased costs for the National Health Service (NHS).
- Recent approvals for oral GLP-1 receptor agonists for weight management could affect obesity treatment strategies.
- There are challenges in ensuring equitable access to these medications, particularly for high-risk patients.
- Oral GLP-1 receptor agonists are not intended to replace established weight management methods but may enhance their effectiveness.
Simplified